UvA-DARE (Digital Academic Repository)
The x-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies
d' Adamo, P.; Fassone, L.; Gedeon, A.; Janssen, E.A.M.; Bione, S.; Bolhuis, P.A.; Barth,
P.G.; Wilson, M.; Haan, E.; Orstavik, K.H.; Patton, M.A.; Green, A.J.; Zammarchi, E.; Donati,
M.A.; Toniolo, D.
Published in:
American Journal of Human Genetics
DOI:
10.1086/514886
Link to publication
Citation for published version (APA):
d' Adamo, P., Fassone, L., Gedeon, A., Janssen, E. A. M., Bione, S., Bolhuis, P. A., ... Toniolo, D. (1997). The xlinked gene G4.5 is responsible for different infantile dilated cardiomyopathies. American Journal of Human
Genetics, 61, 862-867. https://doi.org/10.1086/514886
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s),
other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating
your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask
the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam,
The Netherlands. You will be contacted as soon as possible.
UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
Download date: 20 May 2020
Am. J. Hum. Genet. 61:862–867, 1997
The X-Linked Gene G4.5 Is Responsible for Different Infantile Dilated
Cardiomyopathies
Patrizia D’Adamo,1 Lucia Fassone,1 Agi Gedeon,2 Emiel A. M. Janssen,3 Silvia Bione,1
Pieter A. Bolhuis,3 Peter G. Barth,3 Meredith Wilson,4 Eric Haan,5 Karen Helen Örstavik,6
Michael A. Patton,7 Andrew J. Green,8 Enrico Zammarchi,9 Maria Alice Donati,9 and
Daniela Toniolo1
1
Institute of Genetics, Biochemistry and Evolution-CNR, Pavia, Italy; Departments of 2Cytogenetics and Molecular Genetics and 5Medical
Genetics and Epidemiology, Women’s and Children’s Hospital, North Adelaide, Australia; 3Department of Neurology, Academic Medical
Centre, Amsterdam; 4Department of Clinical Genetics, The New Children’s Hospital, Westmead, Australia; 6Department of Medical Genetics,
Ulleval Hospital, Oslo; 7Department of Medical Genetics, St. Georges Hospital Medical School, London; 8Department of Medical Genetics,
University of Cambridge, Cambridge; and 9Department of Pediatrics, University of Florence, Florence
Summary
Barth syndrome (BTHS) is an X-linked disorder characterized clinically by the associated features of cardiac
and skeletal myopathy, short stature, and neutropenia.
The clinical manifestations of the disease are, in general,
quite variable, but cardiac failure as a consequence of
cardiac dilatation and hypertrophy is a constant finding
and is the most common cause of death in the first
months of life. X-linked cardiomyopathies with clinical
manifestations similar to BTHS have been reported, and
it has been proposed that they may be allelic. We have
recently identified the gene responsible for BTHS, in one
of the Xq28 genes, G4.5. In this paper we report the
sequence analysis of 11 additional familial cases: 8 were
diagnosed as possibly affected with BTHS, and 3 were
affected with X-linked dilated cardiomyopathies. Mutations in the G4.5 gene were found in nine of the patients
analyzed. The molecular studies have linked together
what were formerly considered different conditions and
have shown that the G4.5 gene is responsible for BTHS
(OMIM 302060), X-linked endocardial fibroelastosis
(OMIM 305300), and severe X-linked cardiomyopathy
(OMIM 300069). Our results also suggest that very severe phenotypes may be associated with null mutations
in the gene, whereas mutations in alternative portions or
missense mutations may give a ‘‘less severe’’ phenotype.
Introduction
The dilated cardiomyopathies are a very heterogeneous
group of heart disorders of largely unknown ethiology.
Genetic causes have become increasingly evident with
mapping of loci and identification of genes responsible
Received March 28, 1997; accepted for publication July 11, 1997.
Address for correspondence and reprints: Dr. Daniela Toniolo,
IGBE-CNR, Via Abbiategrasso 207, 27100 Pavia, Italy. E-mail:
[email protected]
q 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6104-0013$02.00
862
for different forms of the disorder (Keating and Sanguinetti 1996). The dilated cardiomyopathies are often
idiopathic, and in adults they represent a primary indication for heart transplantation. Less frequent and more
severe are the infantile forms, which often cause cardiac
failure during the first months of life. One of these severe
forms is Barth syndrome (BTHS), an X-linked inherited
disorder characterized clinically by the associated features of cardiac and skeletal myopathy, short stature,
and neutropenia (Barth et al. 1983). The disease has
infantile onset of symptoms and is often fatal in childhood, because of cardiac failure or sepsis: the clinical
manifestations of the disease are, in general, quite variable also within families, but cardiac failure as a consequence of cardiac dilatation and hypertrophy is a constant finding. Which of the other manifestations of the
disease may also be diagnostic is an open question. Xlinked infantile cardiomyopathies with cardiac dilatation but apparently lacking the other symptoms of BTHS
have been reported, and it has been proposed that the
BTHS may be allelic with both X-linked endocardial
fibroelastosis (EFE1; OMIM 305300) and other infantile cardiomyopathies (Gedeon et al. 1995; OMIM
300069).
BTHS has been localized to Xq28 (Bolhuis et al.
1991). We have recently reported the identification of a
novel gene, G4.5, which we have proposed as the genetic
locus responsible for the disease (Bione et al. 1996). The
G4.5 gene is a small single-copy gene with a complex
pattern of expression. As many as 10 mRNAs differing
either in the region encoded in the central exons (5–7)
or in the 5* end can be synthesized. Two forms, containing all three exons or lacking exon 5 only, were
consistently more abundant and ubiquitously expressed.
Since the differently spliced mRNAs maintain the same
open reading frame (ORF), the tafazzins, the putative
proteins encoded by the gene, can differ in the N-terminus and in a central portion. All the mutations found
in the four familial cases of BTHS studied so far have
introduced a stop codon in the ORF, but in all instances
D’Adamo et al.: X-Linked Dilated Cardiomyopathies
they would not interfere with the synthesis of all the
possible tafazzins. We now report the study of a larger
group, of patients affected with BTHS and of patients
affected with severe cardiac disorders compatible with
X-linked inheritance. We show that mutations are to be
found also in this group of patients and that the G4.5
gene is responsible for most of the X-linked infantile
dilated cardiomyopathies.
Material and Methods
Mutation Detection
Genomic DNA preparation, amplification, and direct
sequencing of the BTHS gene were as described elsewhere (Bione et al. 1996). Sequences were from the
primers described, and they were designed to sequence
all exons and exon-intron junctions from both strands.
As a control for PCR errors, at least two independent
PCR products were sequenced in the region of each mutation. The sequence of each patient was always compared with that of at least one normal individual, in
the same gel. As a control for polymorphism, all the
mutations were searched in DNA from 100 normal
chromosomes randomly selected among different populations available to the laboratory and containing both
males and females.
Sequence Analysis
Sequence reactions were run in a Perkin Elmer 373A
Automated Sequencer, and they were analyzed by use
of SeqEd and Sequence Navigator software. Sequences
were compared with the GenBank sequences by use of
BLAST, and they were aligned with CLUSTAL.
Results
Mutation Analysis of BTHS Patients
In our previous work we studied patients from four
families affected with BTHS. To gain more information
on the mutations causing this disorder, we collected
eight additional cases. Some were definitely familial. In
other families relatives were reported as possibly affected, but the disease could not be well defined before
death occurred. Some of the clinical manifestations of
the propositi of each family are schematically listed in
table 1. Other affected family members were usually
studied less thoroughly and are not reported in the table:
some of the families were previously published, and
more data are available from the literature. In all families, cardiac dilatation and cardiac failure within the
1st year of life were the common feature. Neutropenia
(usually cyclic or episodic), myopathy, growth retardation, and alterations in urinary 3-methylglutaconic acid
(Kelley et al. 1991) were consistently reported. Life expectancy was very variable, possibly depending on medical treatment. Cardiac transplantation was reported in
863
two of the patients (BS and GW) and seems to have
increased life expectancy.
In the search for mutations, PCR products were prepared from genomic DNA of either one patient or an
obligate carrier from each family and were sequenced
directly, as described elsewhere (Bione et al. 1996). Mutations were found in six of the familial cases, and they
are listed in table 1; their localizations with respect to
the G4.5 gene are shown in figure 1. Some of the corresponding sequences are shown, aligned with the normal
sequence, in figure 2.
Two new mutations were found in exon 2, one was
in exon 6, and the remaining three were in exon 8. One
of the mutations in exon 2 (family 1) was a deletion
causing a frameshift and early stop; all the remaining
mutations were missense. As a control for polymorphism, 100 chromosomes from normal individuals were
sequenced in the region of the mutations, and they were
all normal. On the other hand, additional affected individuals and obligate carriers, when available, were sequenced, and the mutations were all confirmed. In family 1 we sequenced the mother’s DNA; in family 6 the
mother’s and the grandmother’s DNAs; in family 8 the
mother’s and the sister’s DNAs; and in family 9 the
mother’s, the aunt’s, and a normal brother’s DNAs.
In the remaining two families, published as putative
BTHS (families 11 and 12; Örstavik et al. 1993), no
mutations were found. Since only the coding region and
the splice junctions were studied, and since only the
DNAs of obligate carriers were available, we cannot
absolutely exclude an involvement of the G4.5 gene.
Four sporadic patients were also studied, and no mutations were found.
X-Linked Infantile Cardiomyopathies: Mutations in the
BTHS Gene
Gedeon et al. (1995) reported a large family presenting with X-linked inheritance of a fatal infantile cardiomyopathy. The gene was mapped to Xq28. The cardiomyopathy in this family is consistently of congenital
onset and is fatal in infancy. The clinical features were
insufficient to permit a definite diagnosis, but the possibility that this disease is allelic with BTHS was discussed.
We sequenced the G4.5 gene in two affected individuals
of the family, and we found deletion of a C at position
919 in exon 8, causing frameshift and a stop codon after
18 nucleotides (patient MH in fig. 1). The mutation may
cause the production of a truncated protein or, possibly,
a reduced amount of the corresponding mRNAs and
therefore no protein at all (Maquat 1995).
We have also studied patients from two families with
several affected male relatives (brothers and cousins)
who died very early of heart failure. The clinical data
were very limited, but after autopsy these patients’
hearts showed left-ventricular dilatation and hypertrophy, and they were diagnosed as affected with EFE1.
864
Table 1
Data on BTHS Patients
Family
1
2
3
4
5
6
7
8
9
10
11
12
Patient
Source
Author
Affected
Relative(s)
BM
V.22
BS
K
GW
FW
OAT
MF
FT
BV
II-1
II-2
R.M.
P.A.B.
M.A.P.
P.A.B.
A.G.
K.H.O.
A.G.
M.A.D.
P.A.B.
P.A.B.
K.H.O.
K.H.O.
Brother
Several (18)
Two brothers
Not proved
Nephew
Brother
Several
Not proved
Not proved
Not proved
Brother
Brother
Referencea
Year of
Birth
Age
(years)
...
1
2
...
...
3
4
...
...
...
3
3
1986
1984
1992
1989
1978
1984
1989
1994
1991
1983
1987
1977
10
5
19
5
16
Age at
Death
(mo)
Dilated
Cardiomyopathyb
Neutropeniab
Living
10
Living
13
Living
9
ú21
14
Living
Living
1
20
/
/
/c
/
/d
/
/
/
/
/
/
/
Cyclic
/
//0
0
Cyclic
/
/
/
Cyclic
/
0
0
Myopathyb
3Methylglutaconic
Aciduriab
Growth
Retardationb
Abnormal
Mitochondriab
Mutation
Exon
Referencea
/
//0
//0
/
0
ND
/
ND
/
/
//0
0
/
/
/
//0
/
ND
ND
/
/
/
ND
ND
/
/
/
/
/
/
ND
ND
/
/
0
0
ND
/
ND
ND
/
ND
ND
ND
ND
ND
/f
/f
428del13
Y51X
H69Q
527-1 GrA
527-1 GrC
F178Ie
868insT
G197R
G216R
G216R
Nonee
Nonee
2
2
2
...
5
...
5
5
...
5
...
...
...
...
...
6
7
8
8
8
a
1 Å Barth et al. (1983); 2 Å Patton et al. (1994); 3 Å Örstavik et al. (1993); 4 Å Àdes et al. (1993); and 5 Å Bione et al. (1996).
/ Å Present; 0 Å absent; //0 Å uncertain status; and ND Å not done.
c
Cardiac transplant at age 4 mo.
d
Cardiac transplant at age 14 mo.
e
Sequence was determined on the basis of the mother’s DNA.
f
Only in myocardium.
b
Am. J. Hum. Genet. 61:862–867, 1997
865
D’Adamo et al.: X-Linked Dilated Cardiomyopathies
Figure 1
Mutations in G4.5 gene, and their localization in a schematic representation of the gene. Blackened boxes are invariant exons;
and diagonally striped boxes are alternatively spliced exons.
One family was published by Lindenbaum et al. in 1973
(Lindenbaum et al. 1973). In the second large and yetunpublished family (fig. 3), four affected males were
described: three (IV-1, IV-16, and V-5) died within the
first 3–4 mo of life of cardiac failure. The fourth, SWH
(IV-4), had cardiac failure at age 5 wk, survived, and
now, at age 25 years, is normal. In both families we
found the same mutation (a GrA change at nucleotide
1006) in exon 10, causing a GrR change in the sequence
of the protein (G240R). The mutation was not found
in 100 normal chromosomes. In the family studied by
Lindenbaum et al., the mutation was found in three
obligate carriers. In the family of SWH, all the patients
and the mother (II-1) of SWH were sequenced and
shown to carry the mutation.
Missense Mutations: Change of Conserved Amino
Acids
The G4.5 gene is conserved in evolution. A BLAST
search of GenBank showed that ORFs encoding very
similar protein sequences exist in Caenorhabditis elegans and Saccharomyces cerevisiae genomes. The alignment of the tafazzins from the three organisms is shown
in figure 4. The region corresponding to the alternative
exon 5 in human is missing in the C. elegans gene; in S.
cerevisiae the corresponding region is present, but it is
not conserved. Striking conservation was observed in
most of the rest of the protein. The four regions boxed
in figure 4 are the most conserved: ú50% of the amino
acids are identical between the three species, and ú80%
are conservative substitutions. The missense mutations
found in the patients are indicated in figure 4, and in all
instances they correspond to residues conserved between
two or all three organisms. No function is known for
the C. elegans or S. cerevisiae tafazzins, since they correspond to ORFs identified by genomic sequencing.
Portions of chromatograms showing mutations in some
Figure 2
patients (BM, BS, and MF [bottom sections of panels]) or in an obligate
carrier (HM [bottom section of panel]), compared with the normal sequence (top sections of panels). Lowercase letters denote intron sequences.
Numbers correspond to nucleotide positions in the cDNA (Bione et al.
1996). Arrowheads point to mutations. A 13-base deletion is boxed.
Discussion
In this paper we have presented the results of a study
of mutations in the BTHS gene, G4.5. We show that
mutations in this gene are found in BTHS and in other
866
Figure 3
Pedigree of family SWH. The asterisk (*) indicates the
‘‘normal’’ male (II-4) carrying the mutation. Blackene boxes denote
affected males; and diagonally striped boxes denote males who died
of heart disorder different from BTHS.
X-linked dilated cardiomyopathies, previously considered
different conditions and listed with different OMIM
numbers (305300 and 300069). The patients diagnosed
as affected with BTHS were often well characterized, and
at least one patient in each family was thoroughly studied.
We have tried to summarize the most common features
of the disease, and the data in table 1 demonstrate that,
in addition to cardiac failure in the 1st year of life, growth
arrest, cyclic neutropenia, and methylglutaconic aciduria
appear to be reliable diagnostic signs of BTHS. Patients
Figure 4
Am. J. Hum. Genet. 61:862–867, 1997
affected with either EFE1 or severe cardiomyopathy have
not been as thoroughly studied, and they were just described as affected with dilated cardiomyopathy. Whether
the other symptoms of BTHS were present cannot be
established with the available clinical data, but our findings suggest that mutations in the G4.5 gene have to be
considered as a possible cause of infantile dilated cardiomyopathies affecting males, even in the absence of the
typical BTHS signs.
Seven different mutations have been reported in this
work. They were searched and not found in 100 normal
chromosomes, and, when DNA of family members was
available, they were shown to segregate with the disease.
The 11 mutations described thus far in the BTHS gene
are null or missense mutations localized in alternative,
as well as in invariant, parts of the gene. Both missense
and null mutations seem to be responsible for a similar
disease, since the clinical characteristics and life expectancy of the patients in each BTHS family do not appear
to profoundly differ. This is unlike the situation in many
other disorders, where missense often causes a phenotype less severe than that caused by null mutations.
However, since comparison with similar sequences in
distant species has indicated that the amino acids
changed by the mutations are highly conserved residues,
the very severe effect of missense mutations could be
ascribed to a drastic structural modification of the pro-
Alignment of amino acid sequence of tafazzins with C. elegans and S. cerevisiae homologues, done by use of CLUSTAL. Asterisks
(*) indicate identical amino acids; and dots indicate conserved amino acids. Highly conserved regions are boxed; and amino acids changed in
the patients indicated are in boldface.
867
D’Adamo et al.: X-Linked Dilated Cardiomyopathies
teins, as a consequence of their substitution with different amino acid.
In the family affected with X-linked fatal infantile
cardiomyopathy (Gedeon et al. 1995), the mutation is
a 1-base deletion in exon 8, causing a frameshift and
eventually a stop codon after 18 nucleotides (patient
MH), and it is unique among the 13 patients studied,
since it causes knockout of all the putative tafazzins.
The very severe clinical manifestations of the disorder
in this family (described in six affected males and in
eight males suspected of being affected) could thus be
related to the severity of the mutation. More patients
should be studied to confirm this observation, but the
results suggest that null mutations in the invariant part
of the tafazzins, near the C-terminus of the protein, may
be rare and may have a more severe phenotypic effect.
The direct study of the tafazzins, by determination of
which are the proteins present in each affected cell type,
will help to further clarify this point.
The function of the G4.5 gene is presently unknown,
nor did the gene product show similarity to known proteins. The sequence of the tafazzins is very conserved in
evolution: ORFs encoding proteins highly homologous
to the tafazzins have been found in S. cerevisiae and C.
elegans. The conservation, together with the very severe
phenotype associated with mutations in the gene, suggests that the role of the tafazzins must be of great importance for the correct function of the heart and other
organs during fetal and neonatal life. In this paper, we
have presented a family in which at least one individual
(SWH) carrying a mutation causing a severe phenotype
had a very severe heart failure but survived to live a
normal life. In the same family, another male (II-4) also
must have carried the mutation: one of his sisters (II-5)
and his daughter (III-15) are obligate carriers, and his
grandson was affected. Despite the mutation, he was
able to reproduce and to transmit the disease. We do
not know much about and cannot study II-4, but the
finding of the SWH patient and the characteristics of his
family suggest that some ‘‘protecting’’ factor(s) could
act in fetal life and early after birth. Accordingly, some
other patients seem to be able to survive to age ú10
years (see table 1 and one patient reported by Christodoulou et al. [1994] who is suspected to have BTHS).
These findings suggest that the role of the tafazzin(s)
may be very important early in life and for a limited
time after birth and that in later life it may be substituted
by other functions. Such function(s) may be responsible
also for the very large phenotypic heterogeneity of the
symptoms within families.
Acknowledgments
We thank Dr. Mueller and Dr. R. Savrirayan for providing
patient DNA and information. We also thank F. liBergolis for
technical assistance. This work was supported by Progetto
Finalizzato CNR Ingegneria Genetica and Telethon Italy (support to D.T.). S.B. is a fellow of the Ph.D. program of the U.
of Pavia.
References
Adès LC, Gedeon AK, Wilson MJ, Latham M, Partington
MW, Mulley JC, Nelson J, et al (1993) Barth syndrome:
clinical features and confirmation of gene localization to
distal Xq28. Am J Med Genet 45:327–334
Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel
JM, Luyt-Houwen IEM, Van’t Veer-Korthof ETH, Van der
Harten JJ, et al (1983) An X-linked mitochondrial disease
affecting cardiac muscle, skeletal muscle and neutrophil leukocytes. J Neurol Sci 62:327–355
Bione S, D’Adamo P, Maestrini E, Gedeon AK, Bolhuis PA,
Toniolo D (1996) A novel X-linked gene, G4.5, is responsible for Barth syndrome. Nat Genet 12:385–389
Bolhuis PA, Hensels GW, Hulsebos TJM, Baas F, Barth PG
(1991) Mapping of the locus for X-linked cardioskeletal
myopathy with neutropenia and abnormal mitochondria
(Barth syndrome) to Xq28. Am J Hum Genet 48:481–485
Christodoulou J, McInnes RR, Jay V, Wilson G, Becker LE,
Lehotay DC, Platt BA, et al (1994) Barth syndrome: clinical
observation and genetic linkage studies. Am J Med Genet
50:255–264
Gedeon AK, Wilson MJ, Colley AC, Sillence DO, Mulley IC
(1995) X linked fatal infantile cardiomyopathy maps to
Xq28 and is possibly allelic to Barth syndrome. J Med Genet
32:383–388
Keating MT, Sanguinetti MC (1996) Molecular genetic insights into cardiovascular disease. Science 272:681–685
Kelley RI, Cheatham JP, Clark BJ, Nigro MA, Powell BR,
Sherwood GW, Sladky JT, et al (1991) X-linked dilated
cardiomyopathy with neutropenia, growth retardation, and
3-methylglutaconic aciduria. J Pediatr 119:738–747
Lindenbaum RH, Andrews PS, Khan ASSI (1973) Two cases
of endocardial fibroelastosis possible X-linked determination. Br Heart J 35:38–40
Maquat LE (1995) When cells stop making sense: effects of
nonsense codons on RNA metabolism in vertebrate cells.
RNA 1:453–465
Örstavik KH, Skjörten F, Hellebostad M, Hågå P, Langslet A
(1993) Possible X linked congenital mitochondrial cardiomyopathy in three families. J Med Genet 30:269–272
Patton MA, Taylor R, Jeffrey S, Jeffrey I, Burn J (1994) Prenatal diagnosis of X-linked cardiomyopathy with neutropenia
(Barth syndrome) using DXS15. J Med Genet 31:169–170